WWP2 Antibody

What is WWP2 and why is it important in research?

WWP2 (WW domain containing E3 ubiquitin protein ligase 2) is a nuclear protein involved in the regulation of transcription and gene expression. In humans, the canonical protein consists of 870 amino acid residues with a molecular mass of 98.9 kDa. WWP2 is significantly expressed throughout the brain, placenta, lung, liver, muscle, kidney, and pancreas in fetal tissues. Its importance in research stems from its role as an E3 ubiquitin ligase that regulates protein degradation through the ubiquitin-proteasome pathway, which is critical for numerous cellular processes including proliferation, differentiation, and cell survival . Understanding WWP2 function has implications for multiple fields including developmental biology, cancer research, and cellular signaling studies.

What are the known isoforms of WWP2 and how do they differ functionally?

Up to four different isoforms of WWP2 have been reported in the literature . These isoforms arise through alternative splicing and have distinct domain compositions that influence their substrate specificity and cellular functions. The full-length WWP2 (WWP2-FL) contains an N-terminal C2 domain, four WW domains, and a C-terminal HECT domain. Other isoforms include WWP2-N (N-terminal region), WWP2-C (C-terminal region), and WWP2-N/C (containing both terminal regions but lacking the middle portion). Each isoform demonstrates different binding preferences for target proteins, resulting in varied regulatory effects on substrates. For instance, some isoforms may preferentially target specific transcription factors, while others might regulate different sets of proteins involved in cellular signaling pathways.

What are the common applications for WWP2 antibodies in research?

WWP2 antibodies are utilized in multiple research applications, with Western Blot (WB) being the most widely employed technique for detecting and quantifying WWP2 protein expression . Other common applications include:

• Immunohistochemistry (IHC): For visualizing WWP2 expression in tissue sections

• Immunofluorescence (IF): For cellular localization studies

• Immunoprecipitation (IP): For isolating WWP2 and associated protein complexes

• Co-immunoprecipitation (CoIP): For studying protein-protein interactions

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection

These techniques enable researchers to investigate WWP2 expression patterns, subcellular localization, protein interactions, and functional roles in various biological contexts .

How should I optimize Western blot conditions for WWP2 detection?

Optimizing Western blot conditions for WWP2 detection requires careful consideration of several parameters:

Since WWP2 has an observed molecular weight of approximately 110-115 kDa (slightly higher than the calculated 99 kDa) , ensure your gel system and transfer conditions are optimized for proteins of this size. Additionally, include positive controls (such as HepG2 or A549 cell lysates) where WWP2 is known to be expressed . If detecting multiple isoforms, be aware that their molecular weights will differ, and optimization may be required to clearly resolve these bands.

What are the critical considerations for immunohistochemical detection of WWP2?

For effective immunohistochemical detection of WWP2, consider the following methodological aspects:

• Antigen Retrieval: Data suggests optimal results using TE buffer at pH 9.0, although citrate buffer at pH 6.0 may also be effective . The choice can be tissue-dependent, so comparing both methods is advisable.

• Antibody Dilution: Start with a dilution range of 1:20-1:200 for IHC applications . The optimal dilution may vary based on the specific tissue being examined and the fixation method used.

• Positive Controls: Include tissues known to express WWP2, such as pancreatic tissue, which has been successfully used in previous studies .

• Blocking Protocol: Thorough blocking with serum-free protein block is critical to reduce non-specific binding, particularly in tissues with high endogenous peroxidase activity.

• Detection System: Use a sensitive detection system appropriate for your tissue type, with DAB (3,3'-diaminobenzidine) being commonly employed as the chromogen.

• Counterstaining: A light hematoxylin counterstain typically provides optimal nuclear contrast without obscuring specific WWP2 staining.

The subcellular localization of WWP2 is primarily nuclear , so proper nuclear staining should be evaluated as a quality control measure for successful IHC procedures.

How can I validate the specificity of a WWP2 antibody for my experimental system?

Validating antibody specificity is critical for reliable results. For WWP2 antibodies, employ these validation strategies:

• Knockout/Knockdown Controls: The most definitive validation method is comparing WWP2 antibody reactivity in wild-type versus WWP2 knockout or knockdown samples. Multiple publications have utilized this approach .

• Overexpression Systems: Test antibody reactivity in cells overexpressing tagged WWP2 constructs.

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide to demonstrate that specific binding is blocked.

• Multiple Antibodies: Compare staining patterns using antibodies targeting different epitopes of WWP2.

• Cross-Species Reactivity: Check consistent detection patterns across species if working with non-human models. WWP2 antibodies often show reactivity with human, mouse, and rat samples .

• Molecular Weight Verification: Confirm that the detected band appears at the expected molecular weight of 110-115 kDa for the full-length protein , recognizing that isoforms will produce bands of different sizes.

• Literature Comparison: Compare your results with published studies utilizing the same or similar antibodies.

Implementing multiple validation strategies provides stronger evidence for antibody specificity than relying on a single approach.

Why might I observe multiple bands when probing for WWP2 in Western blot?

Multiple bands in Western blot analysis of WWP2 can occur for several reasons:

• Isoform Detection: WWP2 has up to four reported isoforms , which would appear as bands of different molecular weights. The full-length protein is approximately 110-115 kDa, while shorter isoforms will produce lower molecular weight bands.

• Post-translational Modifications: WWP2 can undergo various post-translational modifications, particularly ubiquitination (given its function as an E3 ligase), which can alter its migration pattern on SDS-PAGE.

• Proteolytic Degradation: Improper sample handling or insufficient protease inhibitors may result in protein degradation, creating truncated fragments that appear as additional bands.

• Cross-Reactivity: Some antibodies may cross-react with related proteins, particularly other NEDD4 family members that share domain homology with WWP2.

• Non-specific Binding: Poor blocking or high antibody concentration can lead to non-specific binding and extra bands.

To address these issues, optimize sample preparation with fresh protease inhibitors, titrate antibody concentration, and compare results using different WWP2 antibodies targeting distinct epitopes. Consider using WWP2 knockout/knockdown controls to definitively identify specific bands .

What strategies can improve detection sensitivity for low-abundance WWP2?

Enhancing detection sensitivity for low-abundance WWP2 requires optimization at multiple steps:

• Sample Enrichment:

  • Perform subcellular fractionation to concentrate nuclear proteins where WWP2 is primarily localized

  • Use immunoprecipitation to concentrate WWP2 before Western blotting

  • Consider tissue or cell selection based on known expression patterns (WWP2 is notably expressed in brain, placenta, lung, liver, muscle, kidney, and pancreas)

• Technical Optimization:

  • Use high-sensitivity chemiluminescent substrates or fluorescent detection systems

  • Increase protein loading (50-100 μg versus standard 20-40 μg)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Utilize signal amplification systems such as biotin-streptavidin enhancement

  • Consider more sensitive detection methods like capillary Western systems

• Antibody Selection:

  • Choose high-affinity antibodies specifically validated for detecting low levels of WWP2

  • For immunohistochemistry, employ polymer-based detection systems with enhanced sensitivity

  • Use affinity-purified antibodies rather than whole serum preparations

• Protocol Refinements:

  • Optimize transfer conditions for high molecular weight proteins

  • Reduce washing stringency while maintaining specificity

  • Consider using PVDF membranes with higher protein binding capacity

These approaches should be systematically tested to determine which combination provides optimal sensitivity for your specific experimental system.

How can I address non-specific background in immunofluorescence staining of WWP2?

Non-specific background in immunofluorescence staining can be minimized through several methodological refinements:

• Blocking Optimization:

  • Extend blocking time to 1-2 hours at room temperature

  • Test different blocking agents (BSA, normal serum, commercial blocking buffers)

  • Use a combination of protein block and serum from the species of the secondary antibody

  • Include 0.1-0.3% Triton X-100 in blocking buffer for permeabilized samples

• Antibody Conditions:

  • Titrate primary antibody concentrations (begin with higher dilutions, e.g., 1:500-1:1000)

  • Reduce secondary antibody concentration

  • Extend washing steps (4-5 washes of 5-10 minutes each)

  • Pre-adsorb secondary antibodies against cellular proteins

  • Incubate antibodies in blocking buffer containing 0.1-0.2% Tween-20

• Sample Preparation:

  • Optimize fixation conditions (overfixation can increase background)

  • Ensure thorough permeabilization for nuclear proteins like WWP2

  • Include an autofluorescence quenching step

  • For tissue sections, include Sudan Black B treatment to reduce lipofuscin autofluorescence

• Controls and Validation:

  • Include a no-primary antibody control

  • Use WWP2 knockout/knockdown samples as negative controls

  • Compare staining patterns with different WWP2 antibodies

• Imaging Considerations:

  • Optimize exposure settings to avoid saturation

  • Use spectral unmixing if autofluorescence is an issue

  • Consider confocal microscopy for better signal-to-noise ratio

Remember that nuclear proteins like WWP2 may require specific permeabilization protocols to ensure antibody access while maintaining nuclear morphology.

How can I investigate WWP2 protein-protein interactions using antibody-based techniques?

Investigating WWP2 protein-protein interactions can be accomplished through several antibody-based approaches:

• Co-Immunoprecipitation (Co-IP):

  • Use 0.5-4.0 μg of WWP2 antibody per 1.0-3.0 mg of total protein lysate

  • Employ gentle lysis buffers (e.g., NP-40 or CHAPS-based) to preserve protein complexes

  • Consider crosslinking approaches for transient interactions

  • Verify results with reciprocal Co-IPs using antibodies against the interacting partner

  • A549 cells have been successfully used for WWP2 immunoprecipitation studies

• Proximity Ligation Assay (PLA):

  • Combines antibody recognition with DNA amplification to visualize protein interactions in situ

  • Requires antibodies against both WWP2 and its potential interacting partners

  • Provides spatial information about where interactions occur within cells

  • Can detect endogenous protein interactions without overexpression

• FRET/BRET Assays:

  • Requires expression of fluorescently tagged proteins but can be validated using antibodies

  • Useful for studying dynamics of WWP2 interactions in living cells

• Pull-down Assays with Domain-specific Antibodies:

  • Use antibodies targeting specific domains of WWP2 (N-terminal, WW domains, HECT domain)

  • Helps identify domain-specific interactions and functional consequences

• Chromatin Immunoprecipitation (ChIP):

  • For investigating WWP2 interactions with chromatin or transcription factors

  • Particularly relevant given WWP2's role in transcriptional regulation

Each technique offers different advantages for studying WWP2 interactions, and combining multiple approaches provides stronger evidence for biological relevance of identified interactions.

What approaches can differentiate between WWP2 isoforms in experimental systems?

Differentiating between WWP2 isoforms requires strategic experimental design:

• Isoform-Specific Antibodies:

  • Use antibodies targeting unique regions present in specific isoforms

  • Antibodies against the N-terminal region will detect full-length WWP2 and N-terminal isoforms

  • C-terminal antibodies will detect full-length and C-terminal isoforms

  • Verify specificity using overexpression of individual isoforms

• Western Blot Analysis:

  • Optimize gel separation conditions to resolve isoforms of different molecular weights

  • Use gradient gels (4-15%) for better separation of multiple isoforms

  • Compare migration patterns with recombinant isoform standards

  • Analyze results using densitometry to quantify relative isoform abundance

• RT-PCR and qPCR:

  • Design primers spanning unique exon junctions for each isoform

  • Validate primers using isoform-specific expression constructs

  • Quantify isoform-specific mRNA expression levels

  • Correlate with protein expression using isoform-specific antibodies

• Mass Spectrometry:

  • Perform immunoprecipitation using WWP2 antibodies followed by mass spectrometry

  • Identify isoform-specific peptides and post-translational modifications

  • Quantify relative isoform abundance using label-free or labeled quantification

• Functional Studies:

  • Use isoform-specific siRNAs or CRISPR-based approaches

  • Rescue experiments with individual isoforms in knockdown backgrounds

  • Characterize isoform-specific interactomes using BioID or proximity labeling

These approaches, especially when used in combination, enable researchers to distinguish between WWP2 isoforms and investigate their specific functions within cellular contexts.

How can I study WWP2 enzymatic activity using antibody-based methods?

Studying WWP2 E3 ubiquitin ligase activity requires specialized approaches that often incorporate antibody-based techniques:

• In vitro Ubiquitination Assays:

  • Immunoprecipitate WWP2 using validated antibodies (0.5-4.0 μg for 1.0-3.0 mg lysate)

  • Assess enzymatic activity by adding E1, E2, ubiquitin, ATP, and substrate

  • Detect ubiquitinated products using substrate-specific or ubiquitin-specific antibodies

  • Include controls with catalytically inactive WWP2 mutants

• Cellular Ubiquitination Assays:

  • Co-immunoprecipitate WWP2 and its substrate under denaturing conditions

  • Probe for ubiquitination using anti-ubiquitin antibodies

  • Use antibodies specific for different ubiquitin linkages (K48, K63, etc.) to determine ubiquitin chain topology

  • Compare ubiquitination levels with WWP2 knockdown/knockout conditions

• Fluorescent Reporters:

  • Employ fluorescent ubiquitination-based cell cycle indicators (FUCCI)

  • Validate results using WWP2 antibodies in parallel experiments

  • Correlate fluorescent signals with WWP2 expression levels

• Proximity-Based Assays:

  • Use split-luciferase or split-GFP systems to monitor WWP2-substrate interactions

  • Confirm specificity with antibody-based validation

  • Apply in cellular contexts where enzymatic activity occurs naturally

• Antibody-Based Inhibition:

  • Test if specific antibodies targeting WWP2 catalytic domains inhibit activity

  • Use as tools to study WWP2 function in different cellular compartments

When interpreting results, consider that WWP2 activity may be regulated by post-translational modifications or interactions with regulatory proteins, which can be investigated using modification-specific antibodies in combination with activity assays.

How does WWP2 expression vary across tissues and disease states?

WWP2 expression shows distinct patterns across tissues and can be altered in various disease conditions:

In disease states, WWP2 expression alterations have been documented in:

• Cancer: Several studies have reported dysregulated WWP2 expression in various cancers, including pancreatic cancer, which has been successfully detected using WWP2 antibodies in IHC applications . WWP2 may contribute to cancer progression through ubiquitination and degradation of tumor suppressor proteins.

• Fibrotic Diseases: WWP2 has been implicated in the regulation of TGF-β signaling, which plays a central role in fibrosis development. Altered WWP2 expression or activity may contribute to pathological fibrosis in multiple organs.

• Neurological Disorders: Given its high expression in the brain and interaction with atrophin-1 (as AIP2, atrophin-1 interacting protein 2) , WWP2 may play roles in neurological conditions, particularly those involving protein aggregation.

When analyzing WWP2 expression data, it's important to consider isoform-specific expression patterns, as different isoforms may predominate in different tissues or disease contexts, requiring isoform-specific detection strategies.

What are the most reliable cellular models for studying WWP2 function?

Selecting appropriate cellular models is crucial for studying WWP2 function. Based on available evidence:

• Established Cell Lines:

  • A549 cells: Human lung adenocarcinoma cells have been successfully used for WWP2 immunoprecipitation and Western blot studies

  • HepG2 cells: Human hepatocellular carcinoma cells show detectable WWP2 expression in Western blot applications

  • Cell lines from tissues with high endogenous expression: Derived from brain, placenta, lung, liver, muscle, kidney, and pancreas

• Primary Cells:

  • Primary fibroblasts for studying WWP2's role in fibrosis and TGF-β signaling

  • Primary neurons for investigating its neurological functions

  • Primary epithelial cells from tissues with high WWP2 expression

• Model Selection Considerations:

  • Choose models expressing the relevant WWP2 isoforms for your research question

  • Consider models with appropriate expression of WWP2 substrates and interacting partners

  • Validate WWP2 expression and localization in your chosen model using antibodies

  • Consider species differences if working with non-human models (WWP2 antibodies often show reactivity with human, mouse, and rat samples)

• Genetic Modification Approaches:

  • CRISPR/Cas9 for generating WWP2 knockout cell lines as negative controls

  • Inducible expression systems for controlled expression of WWP2 or its isoforms

  • siRNA/shRNA approaches for transient knockdown studies

The choice of model should be guided by your specific research question, with verification of WWP2 expression and function using validated antibodies as a critical first step in experimental design.

How do WWP2 antibody results correlate with functional outcomes in regulatory pathways?

Integrating WWP2 antibody data with functional assessments provides a more comprehensive understanding of its role in regulatory pathways:

• Correlation with Substrate Levels:

  • Measure levels of known WWP2 substrates using specific antibodies

  • Establish inverse correlations between WWP2 expression/activity and substrate stability

  • Perform pulse-chase experiments to determine substrate half-life in relation to WWP2 levels

• Signaling Pathway Analysis:

  • Correlate WWP2 expression/localization with activation states of relevant signaling pathways

  • Use phospho-specific antibodies to assess downstream signaling outcomes

  • Compare WWP2 knockout/knockdown with wild-type conditions to establish causality

• Transcriptional Regulation:

  • Given WWP2's role in transcriptional regulation , correlate its nuclear localization with changes in target gene expression

  • Combine ChIP-seq using WWP2 antibodies with RNA-seq to identify direct transcriptional effects

  • Analyze WWP2 interaction with transcription factors using Co-IP followed by functional assays

• Contextual Considerations:

  • Assess how cellular stress, growth factors, or other stimuli affect WWP2 expression, localization, and activity

  • Consider temporal dynamics, as WWP2 may function differently at various cell cycle stages or developmental timepoints

  • Evaluate how post-translational modifications of WWP2 correlate with its functional outcomes

• Multi-omics Integration:

  • Combine proteomics (using WWP2 antibodies for enrichment) with transcriptomics and functional assays

  • Develop computational models that integrate WWP2 expression data with pathway activation states

  • Validate model predictions using targeted experiments with WWP2 antibodies

This integrative approach helps establish how WWP2 detection using antibodies relates to its functional consequences in complex cellular systems, providing mechanistic insights beyond simple expression analysis.

How can WWP2 antibodies be utilized in high-throughput screening approaches?

WWP2 antibodies can be adapted for high-throughput screening in several innovative ways:

• Automated Immunocytochemistry/Immunohistochemistry:

  • Screen tissue microarrays for WWP2 expression across multiple cancer types or disease states

  • Correlate expression patterns with clinical outcomes

  • Use digital pathology and AI-based image analysis for quantification

• High-Content Screening:

  • Employ fluorescently labeled WWP2 antibodies to monitor subcellular localization changes in response to compound libraries

  • Multiplex with antibodies against WWP2 substrates or pathway components

  • Correlate WWP2 localization/expression with phenotypic outcomes

• Reverse-Phase Protein Arrays (RPPA):

  • Spot cellular lysates from multiple conditions on nitrocellulose-coated slides

  • Probe with validated WWP2 antibodies for quantitative expression analysis

  • Enable screening of hundreds to thousands of samples simultaneously

• Flow Cytometry-Based Approaches:

  • Develop intracellular staining protocols for WWP2 using validated antibodies

  • Use in combination with cell surface markers for tissue-specific analysis

  • Apply in screening compound libraries for modulators of WWP2 expression

• Protein-Protein Interaction Screens:

  • Adapt WWP2 antibodies for luminescence-based proximity assays

  • Screen for compounds that disrupt or enhance specific WWP2 interactions

  • Validate hits using traditional Co-IP approaches

Considerations for high-throughput applications include antibody specificity validation, optimization of signal-to-noise ratio, and development of robust quantification methods, ideally with automated image analysis or data processing pipelines.

What are the challenges in developing isoform-specific WWP2 antibodies?

Developing isoform-specific antibodies for WWP2 presents several technical challenges:

• Sequence Homology Constraints:

  • High sequence similarity between WWP2 isoforms, particularly in conserved domains

  • Limited unique regions for generating isoform-specific epitopes

  • Challenge in identifying sufficiently immunogenic sequences specific to each isoform

• Technical Production Challenges:

  • Difficulty in expressing and purifying specific domains or junctions for immunization

  • Risk of conformational changes in peptide antigens compared to native protein

  • Need for extensive validation to confirm isoform specificity

• Cross-Reactivity Issues:

  • Potential cross-reactivity with other NEDD4 family members sharing domain homology

  • Need for comprehensive negative controls (other isoforms, related family members)

  • Verification in multiple systems expressing different isoform combinations

• Validation Complexities:

  • Requirement for isoform-specific knockouts or knockdowns as validation controls

  • Need for recombinant expression systems for each isoform

  • Challenge in confirming specificity when multiple isoforms are co-expressed naturally

• Application-Specific Considerations:

  • Ensuring epitope accessibility in fixed tissues for IHC applications

  • Maintaining native protein conformation for applications like IP

  • Optimizing for different experimental conditions across applications

Despite these challenges, the development of truly isoform-specific WWP2 antibodies would significantly advance the field by enabling precise study of isoform-specific functions and expression patterns in physiological and pathological contexts.

How might WWP2 antibodies contribute to therapeutic development strategies?

WWP2 antibodies could contribute to therapeutic development through several research and translational applications:

• Target Validation:

  • Use antibodies to confirm WWP2 expression in disease-relevant tissues

  • Correlate expression levels with disease progression or severity

  • Provide evidence for WWP2 as a viable therapeutic target

• Biomarker Development:

  • Develop IHC protocols using WWP2 antibodies for patient stratification

  • Correlate WWP2 expression or localization with treatment response

  • Establish prognostic or predictive value of WWP2 detection in specific disease contexts

• Mechanistic Studies:

  • Elucidate WWP2 involvement in disease pathways using antibody-based techniques

  • Identify critical protein-protein interactions as potential intervention points

  • Map post-translational modifications that regulate WWP2 activity

• Therapeutic Antibody Development:

  • Use insights from research antibodies to develop function-blocking therapeutic antibodies

  • Target specific domains or interactions critical for pathological activity

  • Engineer antibodies for intracellular delivery to disrupt disease-promoting functions

• Drug Discovery Support:

  • Develop antibody-based assays to screen for small molecule modulators of WWP2

  • Monitor WWP2 expression, localization, or activity changes in response to candidate compounds

  • Validate compound effects on WWP2-dependent pathways

• Combination Therapy Rationale:

  • Use antibodies to identify compensatory mechanisms following WWP2 inhibition

  • Provide rationale for combining WWP2-targeted therapies with other agents

  • Monitor treatment effects on WWP2 and downstream pathways

While direct therapeutic applications of WWP2 antibodies may be limited by challenges in intracellular delivery, their utility in characterizing WWP2 biology and supporting drug development programs makes them valuable tools in translational research pipelines.